Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
FDA announced draft guidance addressing the factors and processes the agency will use when evaluating whether to include a bulk drug substance on the approved list for 503B outsourcers. It is one component of a comprehensive compounding policy framework, which the agency released in January.
[/membership]